Prestige Consumer Healthcare Inc. (PBH) stock analysis
Close on Nov 13, 2026Market cap $2.19BP/E 14.3Yield –
StockData Score
Prices as of Nov 13, 2026How the score works
Mixed11 of 30 checks passed
Prestige Consumer Healthcare passes 11 of the 30 checks behind our score; 7 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 5/6
- Growth
- 1/6
- Past performance
- 3/6
- Financial health
- 2/6
- Dividend
- 0/6
What stands out
Margin of safety over 20%
The price is 29.2% below fair value, more than the 20% cushion we look for.
Trading below fair value
The share price of $46.19 is below our fair value estimate of $65.23.
Earnings grew over 5 years
Net income grew 2.9% a year on average over the last five fiscal years.
P/E below its 5-year median
Prestige Consumer Healthcare's P/E of 14.3 is below its own 5-year median of 15.3.
What to watch
Return on equity under 15%
Return on equity was 8.2% over the last twelve months and averaged 8.9% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 8.1%, below the 10% that usually covers the cost of capital.
High debt
Debt is 107% of shareholders' equity, above the 40% we consider low.
Revenue growing under 10% a year
Revenue grew -1.2% a year over the last three fiscal years, short of the 10% we look for.
Valuation5/6
P/E below its 5-year median
Prestige Consumer Healthcare's P/E of 14.3 is below its own 5-year median of 15.3.
P/E below the industry
Prestige Consumer Healthcare's P/E of 14.3 is below the Drugs median of 25.0.
EV/EBITDA above its 5-year median
Prestige Consumer Healthcare's EV/EBITDA of 12.9 is above its 5-year median of 12.2.
P/B below the industry
Prestige Consumer Healthcare's price-to-book of 1.13 is below the Drugs median of 2.09.
Trading below fair value
The share price of $46.19 is below our fair value estimate of $65.23.
Margin of safety over 20%
The price is 29.2% below fair value, more than the 20% cushion we look for.
Growth1/6
Revenue growing under 10% a year
Revenue grew -1.2% a year over the last three fiscal years, short of the 10% we look for.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings growth not accelerating
Net income grew -22.8% over the last twelve months, against a 5-year average of 2.9% a year.
Growing slower than the industry
Revenue grew 5.1% over the last twelve months; the Drugs median is 7.7%.
Guidance raised
Prestige Consumer Healthcare raised its Projected FY'27 Projected FY'27 GAAP Net cash provided by operating activities outlook on Aug 6, 2026.
Gross margin slipping
Gross margin was 52.5% over the last twelve months, against 56.1% a year earlier.
Past performance3/6
Return on equity under 15%
Return on equity was 8.2% over the last twelve months and averaged 8.9% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 8.1%, below the 10% that usually covers the cost of capital.
Return on equity above the industry
Prestige Consumer Healthcare's return on equity of 8.2% is above the Drugs median of -57.0%.
Earnings grew over 5 years
Net income grew 2.9% a year on average over the last five fiscal years.
Net margin below its 5-year average
Net margin was 13.3% over the last twelve months, against a 5-year average of 13.3%.
Net margin above the industry
Prestige Consumer Healthcare's net margin of 13.3% is above the Drugs median of -53.5%.
Financial health2/6
High debt
Debt is 107% of shareholders' equity, above the 40% we consider low.
Debt falling against equity
Debt to equity fell from 109% five years ago to 107%.
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals 11.1% of total debt; we look for at least 20%.
Interest coverage
Interest expense is not reported separately.
Short-term assets cover short-term debts
Current assets are 2.92 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is 1.54; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Prestige Consumer Healthcare has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$65.23
The share price is 29% below this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 20.1× | 15.3× | 25.0× | $65.11 | 40% |
| EV/EBITDA | 14.8× | 12.2× | 17.4× | $59.42 | 35% |
| P/B | 2.0× | 1.9× | 2.1× | $82.63 | 10% |
| Earnings power | 7.6% cost of equity | – | – | $67.50 | 15% |
| Fair value | $65.23 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 15.3
- Drugs median 25.0
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $28.42M
- Value traded per 1% price move
- $14.09M
Downside
Medium risk
- Typical loss in a bad month
- 19.1%
- Volatility (annualized)
- 38%
- Sharpe ratio, 1 year
- -0.75
- Beta to the S&P 500 (5Y)
- 0.44
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -4.3% | -1.2% | +2.9% | +3.0% | |
| Gross profit | -6.1% | -1.6% | +1.7% | +2.5% | |
| Operating income | -8.1% | – | +0.8% | +1.7% | |
| Net income | -11.3% | – | +2.9% | +6.7% | |
| EPS, diluted | -8.9% | – | +3.8% | +7.6% | |
| Free cash flow | +1.3% | +3.6% | +2.9% | +3.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 8.9% | 13.0% | 10.2% | |
| Return on assets | 2.0% | 4.7% | 5.5% | |
| Current ratio | 2.06 | 2.21 | 3.57 | |
| Debt to equity | 2.67 | 1.09 | 0.53 | |
| Net debt to EBITDA | 9.30× | 4.42× | 2.73× | |
| Interest coverage | 2.2× | 3.6× | – | |
| Inventory turnover | 3.7× | 3.4× | 3.2× | |
| Capex to revenue | 0.3% | 2.4% | 1.0% | |
| Diluted shares | 53M | 51M | 49M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Prestige Consumer Healthcare generated $1.25B from operations and spent $329.17M on capital expenditure, dividends and share buybacks. 14% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 17.5% | 0.32× | 1.85× | 10.2% |
| FY2025 | 18.9% | 0.34× | 1.93× | 12.3% |
| FY2024 | 18.6% | 0.34× | 2.15× | 13.5% |
| FY2023 | -7.3% | 0.32× | 2.32× | -5.4% |
| FY2022 | 18.9% | 0.31× | 2.42× | 14.0% |
| FY2021 | 17.5% | 0.27× | 2.75× | 13.0% |
| FY2020 | 14.8% | 0.28× | 3.07× | 12.6% |
| FY2019 | -3.7% | 0.27× | 3.17× | -3.1% |
| FY2018 | 32.6% | 0.27× | 3.83× | 33.9% |
| FY2017 | 7.9% | 0.26× | 4.38× | 8.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
- ProfitableNet income above zero$190.30M
- Cash generatingOperating cash flow above zero$257.63M
- Return on assets improvedROA up on the prior year6.5% → 5.6%
- Earnings backed by cashOperating cash flow above net income$257.63M vs $190.30M
- Less leverageLong-term debt to assets fell– → 28.4%
- Better liquidityCurrent ratio rose4.20 → 3.57
- No dilutionShare count did not rise50M → 49M
- Gross margin improvedGross margin up on the prior year55.76% → 54.71%
- More efficientAsset turnover rose0.34 → 0.32
See a number that looks wrong?